Philogen SpA - ESG Rating & Company Profile powered by AI
This dashboard includes a questions and answers table for Philogen SpA. The ESG score for Philogen SpA indicates its transparency towards the United Nations SDGs. Alternative corporations in the rating peer group for Philogen SpA are shownin the table.
Philogen SpA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.7; made up of an environmental score of 2.0, social score of 0.0 and governance score of 3.2.
1.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1631 | Viewbix Inc | 1.8 | Low |
| 1631 | dorsaVi Ltd | 1.8 | Low |
| 1682 | Philogen SpA | 1.7 | Low |
| 1682 | C4 Therapeutics Inc | 1.7 | Low |
| 1682 | Abcellera Biologics Inc | 1.7 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Philogen SpA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Philogen SpA disclose current and historical energy intensity?
Sign up for free to unlockDoes Philogen SpA report the average age of the workforce?
Sign up for free to unlockDoes Philogen SpA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Philogen SpA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Philogen SpA disclose cybersecurity risks?
Sign up for free to unlockDoes Philogen SpA offer flexible work?
Sign up for free to unlockDoes Philogen SpA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Philogen SpA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Philogen SpA conduct supply chain audits?
Sign up for free to unlockDoes Philogen SpA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Philogen SpA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Philogen SpA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Philogen SpA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Philogen SpA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Philogen SpA disclose water use targets?
Sign up for free to unlockDoes Philogen SpA have careers partnerships with academic institutions?
Sign up for free to unlockDid Philogen SpA have a product recall in the last two years?
Sign up for free to unlockDoes Philogen SpA disclose incidents of discrimination?
Sign up for free to unlockDoes Philogen SpA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Philogen SpA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Philogen SpA disclose parental leave metrics?
Sign up for free to unlockDoes Philogen SpA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Philogen SpA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Philogen SpA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Philogen SpA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Philogen SpA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Philogen SpA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Philogen SpA involved in embryonic stem cell research?
Sign up for free to unlockDoes Philogen SpA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Philogen SpA disclose its waste policy?
Sign up for free to unlockDoes Philogen SpA report according to TCFD requirements?
Sign up for free to unlockDoes Philogen SpA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Philogen SpA disclose energy use targets?
Sign up for free to unlockDoes Philogen SpA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Philogen SpA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Philogen SpA
These potential risks are based on the size, segment and geographies of the company.
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.